Aptevo Therapeutics Inc
$1.73
Market Cap
$3.10M
Shares Outstanding
1.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 20, 2016
Round Lot
100
Locale
US
Day Open
$1.71
Day High
$1.80
Day Low
$1.71
Volume
33.5K
VWAP
$1.76
Prev Close
$1.71
Transactions
--
Acc. Volume
--
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Aptevo Therapeutics Inc (APVO) closed the 2026-09-16 session at $1.73, up 1.17% versus the previous close (+0.02). The stock opened at $1.71 and traded between $1.71 and $1.80 during that session. Session trading volume was 33K shares. The volume-weighted average price (VWAP) is $1.76.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Aptevo Therapeutics Inc has a market capitalization of $3.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. APVO is listed on the XNAS exchange. The company employs approximately 33 people. Aptevo Therapeutics Inc is headquartered in SEATTLE, WA. The recorded listing date is 2016-07-20.
On this page you can find market APVO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.